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Background: Dengue is endemic to the tropics and subtropics, and the most frequent of arthropod-borne viral
diseases. Reliable diagnosis of dengue infection is important not only in clinical care but also in disease surveillance, the
control of outbreaks, and the development of new vaccines. The diagnosis of dengue infection is usually established by
a variety of commercial or in-house serological protocols. The European Network for the Diagnostics of Imported Viral
Diseases (ENIVD) recognized the need to survey the accuracy of dengue serological diagnostics in current use, and
organized an external quality assurance (EQA) study of dengue serological practice in diagnostic laboratories.
Methods: A 15-sample panel, consisting of sera reactive against dengue plus specificity and negative controls, was sent
to 48 laboratories for serological testing. The results returned by the participating laboratories were anonymized, scored,
and subjected to comparison and statistical analysis.
Results: Ten laboratories rated all samples correctly with regard to IgM, and only three achieved the full score for IgG
detection. The main handicaps in assay performance were suboptimal sensitivity of in-house IgM detection protocols by
comparison with better-performing commercial ELISA tests, and the presence of IgG cross-reactivity with heterologous
flaviviruses. Differences of detail in the methodology of dengue IgG antibody detection appear to underlie the disparities
in accuracy observed between laboratories.
Conclusion: This EQA study demonstrates that there is room for many laboratories to improve sensitivity in the
detection of anti-dengue virus IgM antibodies, against the benchmark set by commercial antibody capture ELISA tests.
The EQA shows also that cross-reactivity is a continuing issue, and IgG detection protocols must be optimized to
increase their specificity.
Keywords: Dengue, Serology, External quality assessment, Dengue IgM, Dengue IgGBackground
Dengue viruses (DENV; family Flaviviridae, genus
Flavivirus) are transmitted by Aedes sp. mosquitoes
and comprise four genetically and antigenically dis-
tinct serotypes (DENV1—4). Infection with one DENV
serotype leads to lifelong protection against a homolo-
gous challenge, but only brief cross-protection against
heterologous infection [1].
Dengue is one of the most widespread arboviruses.
Nearly 2.5 billion adults and children are at risk of den-
gue infection in the tropics and subtropics, together with
120 million travellers to these regions every year [2].* Correspondence: Domingo-CarrascoC@rki.de
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unless otherwise stated.Children are at a greater risk of life-threatening manifes-
tations of infection [3]. According to World Health
Organization (WHO) estimates, 100 million people are in-
fected with DENV annually, and 500,000 develop the more
severe dengue haemorrhagic fever (DHF). The incidence
of dengue, however, is probably underreported, as endem-
icity areas include countries where notification is lax and
laboratory diagnosis not always available [3].
In Europe, dengue is largely an imported disease, with
hundreds of cases every year among European travellers
returning from the tropics [4]. Travellers are also potential
carriers of the more virulent dengue strains into endemic
areas with milder resident strains, but also into non-
endemic areas where the mosquito vector is present [5].
Therefore, the recent introduction of Aedes albopictus toral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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disease within Europe [6,7]. The epidemiology of dengue
in Europe has deteriorated over the last few years. Spo-
radic cases of autochthonous dengue have been reported
recently from France [8,9] and Croatia [10,11]. In 2012,
Europe experienced the first large, autochthonous dengue
outbreak since an outbreak in Greece in the 1920s: a total
of 2,103 probable and confirmed cases were reported from
the island of Madeira, Portugal [5,12], along with 78 cases
imported into other European countries [12]. Regardless
of the imported or autochthonous origin of the infection,
timely and accurate diagnosis of dengue is crucial to rule
out differential diagnoses and guide clinical care, but also
in epidemiological surveillance, outbreak intervention, and
vaccine development [3,13].
The laboratory diagnosis of dengue relies on tests
for DENV infection markers in patient serum. Virus
isolation and the detection of viral antigens or genomic
RNA can be used for diagnostic purposes during the
early phase of illness. At the end of the acute phase of
infection, beyond 5 to 6 days after onset, a serological
assay for anti-DENV antibodies is the method of choice.
Different patterns in the antibody response are observed
depending on the primary or secondary nature of den-
gue infection [13,14]. In primary infections, the IgM
antibody response can be measured after the decline of
viraemia, between days 3 to 5 after the onset of infec-
tion, and persists for approximately six months. In se-
condary infections, the duration and magnitude of the
IgM response are reduced. The IgG antibody response,
which in primary infection develops a few days after the
onset of the IgM antibody response, may persist for
many years. In secondary infections, the IgG response is
fast, occurring 2–3 days after illness onset, and of
greater magnitude than that in primary infections. Sero-
logical tests are widely used for dengue diagnosis be-
cause of their convenience and their reduced cost
compared to molecular assays. Cross-reactivity with
other circulating flaviviruses is the major obstacle in the
serological diagnosis of dengue infections, but false posi-
tives have also been observed in sera from patients with
malaria or leptospirosis [15].
The European Network for Imported Viral Diseases
(ENIVD) is a laboratory surveillance network for imported,
rare and emerging viral diseases of serious threat to public
health. ENIVD is concerned with the development of
laboratory diagnostic capability, quality control, stan-
dardization of laboratory procedures, and laboratory staff
training (http://www.enivd.de) [2]. ENIVD is currently
composed by 58 qualified or national reference laboratories
(including microbiologists, clinicians, medical scientists,
biologists, epidemiologists, chemists, and veterinarians)
based at public health institutes and universities in 39
countries, including 27 European Union member states,Norway, Turkey, Bosnia and Herzegovina, Croatia,
Kosovo, Serbia, the former Yugoslav Republic of
Macedonia, Albania, Switzerland, and Russia. These la-
boratories support the surveillance and detection of emer-
ging and vector-borne pathogens for the public health
institutions in their respective countries [16]. ENIVD
regularly organizes external quality assessment (EQA) ac-
tivities to assess the ability of participating laboratories to
correctly detect, identify, characterize and diagnose spe-
cific pathogens. We report here on the second ENIVD
dengue serology EQA that surveyed the serological diag-
nostic capacity for dengue infections, and the performance
of laboratories using different in-house or commercial
assays. This EQA aimed to identify possible weaknesses in
the practice of serological tests that could compromise the
diagnosis or surveillance of dengue infections.
Methods
Participants
Fifty-nine institutions involved in laboratory diagnostics of
DENV infection were invited to participate in this study.
Invitees were members of the ENIVD, national or regional
dengue reference laboratories, and dengue tests manufac-
turers. The study was announced as an EQA study on
DENV serological diagnostic proficiency, which included
certifying and publishing the results in a comparative and
anonymous manner. Forty-eight laboratories (response
rate: 81.3%) took part to the EQA under the coordination
of ENIVD: 13 laboratories (27%) from endemic countries,
and 35 from non-endemic areas, namely 33 European
countries, Iran, and Israel (Additional file 1).
Specimen preparation and dispatch
A 15-sample panel (Figure 1) was assembled for distribu-
tion to the participating laboratories. Four samples (#2, #7,
#9, and #4) represented a sensitivity control consisting of
serial two-fold dilutions of a recent dengue infection serum
sample from Costa Rica, known to contain both anti-
DENV IgM and IgG. Samples #14 (IgM+/IgG±/NS1+) and
#15 (IgM+/IgG+/NS1+) were obtained from acutely ill pa-
tients during the aforementioned DENV-1 outbreak in
Madeira, regarded as the most recent European dengue
outbreak. Three further samples examined possible vari-
ation in the stability of target antibodies; for this, the same
serum sample was formulated by three different proce-
dures: one aliquot was processed by lyophilization as the
reference method (#12), another aliquot was lyophilized
with a preserving agent (Formulation-C, Biomatrica, CA,
USA) that increases the stability of proteins at room
temperature (#3), and the third aliquot was simply mixed
with a specific protein stabilizer (SM162, from Biomatrica)
intended to obviate further processing (#13). In addition,
the panel included 4 specificity controls (#1, #10, #6, and
#11) in the form of IgM+, IgG+ sera from patients infected
Figure 1 Dengue serology external quality assurance sample panel composition. NEG: negative; DENV; dengue virus; TBEV: Tick borne
encephalitis virus; YFV: yellow fever virus; JEV: Japanese encephalitis virus; WNV: West Nile virus. α: SM162 reagent included; β: Formulation-C
reagent included.
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Japanese encephalitis and West Nile virus respectively).
Lastly, 2 samples of flavivirus-negative human plasma
(#5 and #8) were included as true negative controls.
The non-dengue, flavivirus-positive sera used as speci-
ficity controls in the panel were from the Robert Koch
Institute collection and their use was approved by the
Charité medical ethics committee (EA1/068/10). The
positive dengue sera in EQA samples #14 and #15 were
provided by author MJA and belong to the reference
collection of the Center for the Study of Vectors and In-
fectious Diseases (CEVDI, Águas de Moura, Portugal).
The sera were collected and use in accordance with eth-
ical regulations from the National Institute of Health,
Portugal, in a codified database preserving the confiden-
tiality of personal data. The sera purchased from Sera
Care Life Sciences (Milford, MA, USA) to prepare the
rest of dengue positive samples in the panel (samples #2,
#7, #9, #4. #12, #13, and#3) were obtained from volun-
teers at FDA-regulated donation centers, with strict ad-
herence to federal HIPAA (Health Insurance Portability
and Accountability Act) regulations. The study was con-
ducted according to the principles of the Declaration of
Helsinki.
The samples tested positive by in-house immuno-
fluorescence assays in the respective laboratories. Sam-
ple validation was carried out at the Robert Koch
Institute, as follows. The samples were screened by a
commercial immunofluorescence assay (Flavivirus IFA
Mosaik, Euroimmun AG, Lübeck, Germany). Those
samples processed by freeze-drying (all except #13,
which was mixed with a stabilizing agent and left in li-
quid form) were subjected to commercial immuno-
fluorescence assays (Flavivirus IFA Mosaik and Dengue
(1–4) IFA Mosaik, both from Euroimmun AG), and
quantitatively titrated by ELISA (IgM capture/indirect IgG
ELISA, Panbio, Brisbane, Australia). Lastly, qualitativeresults were validated externally by the National Institute
of Health in Águas de Moura, Portugal, and the sam-
ples were serotyped at the Bernhard-Nocht Institute in
Hamburg, Germany, using an in-house ELISA assay.
The sample panel was then shipped to each participa-
ting laboratory at room temperature by regular mail,
together with directions to reconstitute the samples by
adding 100 μl of distilled water, and a reporting chart
template for returning the results and relevant me-
thodological information.
Evaluation of the results
The results from each laboratory were anonymized for
data processing under a numerical identification code,
with the suffix a, b, or c appended to identify a set
among multiple sets sent by one laboratory based on
different methods. The results were scored with regard
to sensitivity and specificity. One point was given for
each correct dengue-positive or dengue-negative assign-
ment. False-negative results received no points, whereas
false positive results were penalized with a negative
point. Equivocal or borderline results were considered as
positive. IgM and IgG results were considered separately.
Sample #14 was not scored for IgG as it was known to
contain extremely low IgG levels. The complete panel of
results was sent to the participants in an anonymous
manner so that they could only identify the results from
their own laboratory.
Statistical analysis
The data collected were tabulated in a Microsoft Excel
worksheet (Microsoft Corp., Bellingham, WA, USA) and
analyzed using the SPSS 14.0 software for Windows
(SPSS Inc., Chicago, IL, USA). Evaluation of the analy-
tical sensitivity (the ability to detect true positives) in-
volved the serum samples positive for DENV: #2, #7, #9,
#4, #14, #15, #12, #13, and #3. The evaluation of
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samples) involved samples #1, #10, #6, #11, #5, and #8.
The data on categorized variables, such as scores and
the proportion of correct results, were analyzed by Fisher’s
exact test, two-tailed. Results were considered statistically
significant at the p < 0.05 level.
Results
The 48 participating laboratories (see Additional file 1)
returned a total of 55 sets of IgM results, including three
double and two triple sets from laboratories using more
than one method in parallel (2a and 2b; 6a, 6b and 6c; 7a,
7b and 7c; 32a and 32b; 46a and 46b), and 47 sets of IgG
results, including three double and one triple sets (2a and
2b; 6a and 6b; 7a, 7b and 7c; 32a and 32b), as listed in
Additional file 2 and Additional file 3. Forty-three labora-
tories (89.6%) tested for both IgM and IgG antibodies, and
only 6 laboratories (12.5%), mainly from endemic areas,
tested for IgM alone in their routine diagnosis (laborato-
ries 21, 38, 42, 44, 47, and 48) (Additional file 1).
A variety of methods were used by participating labora-
tories to screen the sera: ELISA (IgM, n = 42 [76.4%]; IgG,
n = 33 [70.2%]), indirect immunofluorescence (IIF; IgM,
n = 11 [20%]; IgG, n = 13 [27.6%]), and rapid immunochro-
matographic tests (IgM, n = 2 [3.6%]; IgG, n = 1 [2.1%]).
In-house assays contributed 1 in 7 IgM data sets (ELISA,
n = 5 [11.9%]; IIF, n = 3 [27.3%]), and 1 in 6 IgG data sets
(ELISA n = 4 [12.1%]; IIF n = 4 [30.8%]). Among the data
involving commercial tests, the Panbio ELISA assays were
those used most frequently (IgM: 11 out of 47 data sets
[23.4%]; IgG: 11 out of 39 data sets [28.2%]), followed by
the Novatec ELISA assays (IgM: 8 out of 47 data sets
[17%]; IgG: 6 out of 39 [15.4%]). No laboratories reported
the use of haemagglutination inhibition or immunoblot
tests.
Dengue NS1 antigen detection, which was not part of
the EQA specification, was performed by only four la-
boratories but we can not rule out wider application of
this assay in the routine diagnosis of acute cases.
The mean score overall for IgM detection was 11.5,
with 78.5% correct positive or negative sample assign-
ments on average (Additional file 2), but performance
varied among laboratories depending on the assay used:
ELISA (mean score of 12 and 81.3% average correct
assignments), IIF (9.6 and 69.7%) or rapid immuno-
chromatographic tests (10 and 67%). The mean score
achieved by laboratories using commercial assays was
12.1 (returning 82% correct results on average), while
the mean score for those using in-house techniques
was 8.8 (64.4% average correct results). Among IgM
assays, statistically significant differences in the propor-
tion of correct results were observed between ELISA
and IIF (p < 0.001), and between commercial and in-
house assays (p < 0.0001).As regards the 55 sets of results for IgM antibodies, 10
out of the 11 laboratories using the Panbio Dengue IgM
capture assay achieved a full set of 15 correct calls across
the sample panel, followed by 5 of the 6 laboratories
using the Dengue Virus IgM Capture DxSelect test from
Focus Diagnostics with 14 correct calls. Lower scores by
the other assays issued mainly from incorrect IgM non-
detection. The laboratories using the Novatec Indirect
Dengue IgM ELISA failed to detect IgM below a titre of
1:1600. The Euroimmun IIF and ELISA assays displayed
lower sensitivity on samples #7, #9, and #4, which may
be related to the DENV-3 serotype shared by these sam-
ples. The sensitivity of the SD Dengue Duo IgM/NS1
and IgM capture ELISA tests was restricted to samples
with a titre above 1:3200 (Additional file 2).
Conclusions can be drawn about the sensitivity and
specificity of the different IgM detection methods from
same-sample comparisons of the rate of correct calls
achieved by each, notably from the comparison between
ELISA and immunofluorescence assays. The overall sen-
sitivity for IgM detection was 66.7% (95% confidence
interval (CI): 62.3% to 70.8%) with 95.1% specificity (95%
CI: 92.2% to 97.2%). Laboratories using commercial
ELISA tests showed the highest sensitivity compared
with those using commercial IIF and in-house ELISA or
IIF assays (Table 1). The commercial IIF assays were of
limited sensitivity in detecting the serological immune
response against DENV-3, while their sensitivity to anti-
DENV-1 IgM antibodies was much better, as was their
specificity profile (Table 2). The high sensitivity demon-
strated through the use of commercial IgM capture for-
mats clearly stands out by comparison with indirect
assays, which were on a level with IIF assays (Table 1).
Concerning the specificity of the different assays, no
major problems were noted in the results of IgM detection
returned by the majority of laboratories. Nonetheless, six
sets of results presented cross-reactivity on non-dengue
flaviviral infection samples, and three laboratories made
false-positive calls on the negative control samples, #5 and
#8 (Additional file 2). Two laboratories in the EQA re-
ported performing a confirmatory background substrac-
tion assay following isolated IgM detection [14] in sample
#14. Results from commercial and in-house ELISA tests
were of comparable specificity, and no differences in spe-
cificity were observed between IgM capture and indirect
assays. In this regard, however, those laboratories using in-
house IIF assays were at a clear disadvantage compared to
those reporting the use of commercial IIF tests, which
showed here a specificity profile similar to that of the
ELISA assays (Table 1 and Table 2).
Regarding anti-dengue IgG detection, only three la-
boratories achieved a full set of correct assignments
across the EQA sample panel. Performance was not re-
lated to a specific method, and optimal results were
Table 1 Analytical sensitivity and specificity showed by the different ELISA and IIF assays used by the participant
laboratories
IgM sensitvity IgM specificity IgG sensitivity IgG specificity
Overall* 66.7% (95% CI 62.3%-70.8%) 95.1% (95% CI 92.2%-97.2%) 84.4% (95% CI 80.6%-87.7%) 83% (95% CI 78%-87.1%)
ELISA assays 70.4% (95% CI 65.5%-75%) 97.2% (95% CI 94.4%-98.9%) 83.2% (95% CI 78.5%-87.3%) 83.8% (95% CI 78%-88.7%)
ELISA commercial 75.5% (95% CI 70.3%-80.2%) 97% (95% CI 93.7%-98.9%) 82.4% (95% CI 77.3%-86.8%) 84.5% (95% CI 78.2-89.5%)
Capture assays 82.7% (95% CI 77%-87.4%) 96% (95% CI 91.5%-98.6%) 59.3% (95% CI 45%-72.4%) 97.2% (95% CI 85.4%-99.5%)
Indirect assays 55.6% (95% CI 44%-66.6%) 100% (95% CI 93.3%-100%) 88.9% (95% CI 83.9%-92.9%) 82.6% (95% CI 75.2%-88.5%)
ELISA in house 48.6% (95% CI 35.6%-60.7%) 97.9% (95% CI 88.9%-99.6%) 88.9% (95% CI 73.9%-96.8%) 79.2% (95% CI 57.8%-92.8%)
IIF assays 56.6% (95% CI 46.2%-66.5%) 86.4% (95% CI 75.7%-93.6%) 88.9% (95% CI 81.7%-93.9%) 79.5% (95% CI 68.8%-87.8%)
IIF commercial 59.7% (95% CI 47.5%-71.1%) 97.9% (95% CI 88.9%-99.6%) 88.9% (95% CI 79.9%-94.8%) 77.7% (95% CI 64.4%-87.9%)
IIF in house 48.1% (95% CI 28.7%-68%) 55.5% (95% CI 30.8%-78.4%) 88.9% (95% CI 73.9%-96.8%) 83.3% (95% CI 62.6%-95.2%)
*ELISA, IIF, and rapid test included. Due to the small number of data sets, rapid test were excluded from further analyses.
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sensitivity was 84.4% (95% CI: 80.6%-87.7%), and specifi-
city was 83% (95% CI: 78%-87.1%) (Table 1). The mean
score for IgG detection was 11.5 with 89.3% correct re-
sults on average, similar to the results from ELISA (11.5
and 89.1%) and IIF (11.5 and 90.2%) assays. The mean
score for laboratories using commercial assays was 11.4
(89% correct results), and 11.7 (91.1% correct results) for la-
boratories using in-house tests. No statistically significantTable 2 Number of correct IgM qualitative results per panel s
ELISA
Sample
code
Sample
content
Sample
titer
Total data sets In-housea
n = 55 n = 8
n % n %
Den#02 DENV-3 1:3200 35 63.6 3 37.5
Den#07 DENV-3 1:1600 28 50.9 3 37.5
Den#09 DENV-3 1:800 21 38.2 1 12.5
Den#04 DENV-3 1:400 12 21.8 0 0
Den#12 DENV-1 1:3200 50 90.9 6 75
Den#14 DENV-1 1:800 29 52.7 1 12.5
Den#15 DENV-1 1:6400 54 98.1 7 87.5
Den#13 DENV-1 1:3200 51 92.7 7 87.5
DEN#03 DENV-1 1:3200 53 96.3 7 87.5
DEN#01 TBEV 53 96.3 7 87.5
DEN#10 YFV 51 92.7 8 100
DEN#06 JEV 52 94.5 8 100
DEN#11 WNV 52 94.5 8 100
DEN#05 NEG 53 96.3 8 100
DEN#08 NEG 53 96.3 8 100
NEG: negative; DENV; dengue virus; TBEV: Tick borne encephalitis virus; YFV: yellow
indirect immunofluorescence.
*not statistically representative.
a: Details not presented; b: PanBio IgM capture ELISA (n = 10), NovaTec Dengue virus Ig
Anti-Dengue Virus ELISA (IgM) (n = 3), InBios DENV Detect IgM capture ELISA (n = 2), St
(n = 2), Dengue virus IgM ELISA IBL International (n = 1); c: Euroimmun DEN1-4 IFA Mos
(SD) dengue Duo IgM/NS1 (n = 2).differences were found between the correct call rates
achieved with the different tests (p > 0.05) with sensitivities
ranging from 82.4% to 88.9% (Table 1).
No major sensitivity issues were observed across the
anti-DENV IgG-positive samples in the test panel, but
34 out of 47 sets of results (72.3%) included a cross-
reactive, false-positive assignment of the serum from a
WNV-infected patient (sample #11). Low specificity is
mentioned as a potential complication by commercialample and technology type
IIF Rapid
testdCommercialb In-housea Commercialc
n = 34 n = 3 n = 8 n = 2
n % n % n % n %*
27 79.4 0 0 5 62.5 0 0
21 61.8 1 33.3 1 12.5 0 0
16 47 2 66.6 2 6.25 0 0
11 32.3 1 33.3 0 0 0 0
32 94.1 1 33.3 7 87.5 2 100
22 64.7 2 66.6 5 62.5 0 0
34 100 3 100 8 100 2 100
34 100 1 33.3 7 87.5 2 100
34 100 2 66.6 8 100 2 100
33 97 3 100 8 100 2 100
33 97 1 33.3 7 87.5 2 100
33 97 2 66.6 8 100 2 100
33 97 1 33.3 8 100 2 100
34 100 1 33.3 8 100 2 100
32 94.1 2 66.6 8 100 2 100
fever virus; JEV: Japanese encephalitis virus; WNV: West Nile virus, IIF:
M-ELISA (n = 8), FOCUS Dengue virus IgM capture DxSelect (n = 6), Euroimmun
andard Diagnostics (SD) Dengue IgM capture ELISA (n = 2), Vircell IgM ELISA
aik (n = 6), Euroimm Flavivirus IFA Mosaik (n = 2); d: Standard diagnostics
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in laboratories applying different assays. No statistically
significant differences in the number of false positives
were observed between laboratories using commercial
versus in-house protocols, or ELISA versus IIF tests. A
review of the proportion of correct results for each
serum sample revealed no differences between these
assay categories with regard to specificity (Table 3).
In the results for the cross-reactivity control samples,
incorrect IgG-positive calls were made by some, but not
all, laboratories using the dengue virus IgG DX Select
assay from Focus Diagnostics or the Novatec dengue
virus IgG ELISA. In addition, only some of the labora-
tories using the Euroimmun Flavivirus Mosaik assay
correctly identified the presence of antibodies against
other (non-dengue) flaviviruses. Overall, this suggests
that the specificity profile does not depend exclusively
on assay design but also on the actual details of labora-
tory procedures. The laboratories using the assays from
Standard Diagnostics (Dengue IgG capture ELISA and
Bioline dengue IgM/IgG) were free from cross-reactivity
in their results, probably at the cost of lower sensitivity.
Likewise, three laboratories (participants #35, 36, and
45) using the Panbio Dengue IgG capture assay avoided
a false-positive call on sample #11 containing anti-WNV
antibodies. These laboratories reported the use of aTable 3 Number of correct IgG qualitative results per panel s
Sample
code
Sample
content
Sample
titer
ELISA
Total data sets In-housea
n = 47 n = 4
n % n %
Den#02 DENV-3 1:3200 47 100 4 100
Den#07 DENV-3 1:1600 43 91.5 4 100
Den#09 DENV-3 1:800 41 87.2 4 100
Den#04 DENV-3 1:400 38 80.8 4 100
Den#12 DENV-1 1:6400 47 100 4 100
Den#14 DENV-1 <1:10 5 10.6 0 0
Den#15 DENV-1 1:25600 47 100 4 100
Den#13 DENV-1 1:6400 46 97.9 4 100
DEN#03 DENV-1 1:6400 45 95.7 4 100
DEN#01 TBEV 45 95.7 4 100
DEN#10 YFV 45 95.7 4 100
DEN#06 JEV 41 87.2 4 100
DEN#11 WNV 13 27.6 1 25
DEN#05 DENV neg. 45 95.7 3 75
DEN#08 DENV neg. 45 95.7 3 75
NEG: negative; DENV; dengue virus; TBEV: Tick borne encephalitis virus; YFV: yellow
immunofluorescence;*not statistically representative.
a: Details not presented; b: PanBio indirect IgG ELISA (n = 11), NovaTec Dengue virus Ig
Virus ELISA (IgG) (n = 2), InBios Dengue Detect IgG Capture ELISA (n = 1), Standard Diag
International (n = 1); c: Euroimmun IFA Dengue 1–4 Mosaik (n = 7), Euroimmun IFA Flavhigher cut-off value for IgG levels in secondary infec-
tions, so that they also experienced a loss in sensitivity
(Additional file 3). Laboratories using commercial cap-
ture assays for dengue IgG detection clearly achieved a
higher degree of specificity than those using indirect for-
mats, but this was associated with much lower sensitivity
(Table 1).
Discussion
We have reviewed here the results from the second
DENV serological diagnosis EQA, carried out under the
auspices of the ENIVD network. An external quality
assessment of laboratory diagnostics such as this one is
a process to survey the sensitivity and specificity of
current methods for detecting viral infection, identify
weaknesses in the proficiency of individual laboratories,
and provide participating centres with advice and assis-
tance. There is increasing recognition among the dengue
community of the need for quality assessments, and the
present study brought together a higher number of la-
boratories, 48, than in previous occasions. Results were
gathered from laboratories in countries with different
epidemiological situations (endemic versus non-endemic),
which had an impact on the diversity of the methods re-
ported and the complexity of the data collected. Labora-
tories from endemic areas, in particular, may provideample and technology type
IIF Rapid
testdCommercialb In-housea Commercialc
n = 29 n = 4 n = 9 n = 1
n % n % n % n %*
29 100 4 100 9 100 1 100
26 89.6 4 100 8 88.8 1 100
24 82.7 4 100 9 100 0 0
22 75.9 4 100 8 88.8 0 0
28 96.5 4 100 9 100 1 100
3 10.3 0 0 2 22.2 0 0
29 100 4 100 9 100 1 100
28 96.5 4 100 9 100 1 100
27 93.1 4 100 9 100 1 100
29 100 4 100 7 77.7 1 100
28 96.5 4 100 8 88.8 1 100
25 86.2 4 100 7 77.7 1 100
9 31 0 0 2 22.2 1 100
28 96.5 4 100 9 100 1 100
28 96.5 4 100 9 100 1 100
fever virus; JEV: Japanese encephalitis virus; WNV: West Nile virus, IIF: indirect
G-ELISA (n = 6), FOCUS Dengue Virus IgG DxSelect (n = 5), Euroimmun Anti-Dengue
nostics (SD) Dengue IgG capture ELISA (n = 2), Dengue Virus IgG ELISA IBL
ivirus Mosaik (n = 2) d: Standard diagnostics (SD) dengue IgM/IgG (n = 1).
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locally (i.e. assays from Standard Diagnostics), the use of
different diagnosis algorithms (diagnosis of primary versus
secondary infections), or the preparedness for surveillance
of countries where this competence is most needed.
The design of the EQA enabled participants to test well-
characterized samples of different origin and measure
their own performance against that of other laboratories.
In this way, they may identify shortcomings in their proto-
cols which otherwise would remain undetected. They also
gained access to valuable reference material that they may
use after the EQA for the improvement or development of
their assays. The comprehensive panel of samples distri-
buted to the participating laboratories included sera of pa-
tients from endemic areas, infected with either DENV-1
or DENV-3, and also two DENV-1 sera from the most re-
cent outbreak of autochthonous dengue in Europe, which
affected the island of Madeira. The inclusion of sera from
non-dengue flaviviral infections made the EQA data
particularly valuable, as it is well-recognized that cross-
reactivity is the major barrier to specific serological diag-
nostics for a target flavivirus. This may constitute a serious
problem for surveillance in countries where more than
one flavivirus circulates [3].
This EQA focused at the outset on the diagnostic accu-
racy of individual laboratories, and the body of data was
ultimately large enough to provide indications on the per-
formance of the different assays in use. Superior sensitivity
was attained by laboratories using capture ELISA tests for
the detection of IgM, specifically those from Panbio and
Focus. Laboratories performing other assays, like the
Euroimmun Flavivirus and Dengue Mosaik assays, varied
in their results depending mainly on the laboratory. In this
regard, it must be noted that immunofluorescence-based
assays can be very useful tools but their results depend
very much on the expertise of the operator and the quality
of the microscopy. This was particularly evident in the
panel of IgG results where, among laboratories using the
same immunofluorescence-based assay, only some were
able to discriminate between dengue and an infection by
another flavivirus.
Since the finding that sera from patients with coinci-
dent diseases may give false-positive IgM, some assay
manufacturers (e.g. Focus) recommend the use of a con-
firmatory assay in their instructions. Only two labora-
tories in the EQA reported performing a confirmatory
background substraction assay following isolated IgM
detection in a sample. Although many laboratories are
aware of the potential for false-positives in their routine
diagnostics and of the advantages of a confirmatory
background substraction assay, they opt against this add-
itional test as it would double the cost per sample.
We observed no significant differences in IgG assay per-
formance between commercial and in house protocols, orbetween different test formats (Table 1). There was a
marked difference, by contrast, between commercial and
in-house tests for IgM. Indeed, in-house IgM ELISA tests
are generally of lower sensitivity compared to commercial
methods, where sensitivity is greatly improved through
the antibody capture approach. In parallel, commercial IIF
assays for IgM detection were found to detect DENV-1 in-
fection with higher sensitivity than DENV-3 (Table 2).
This may explain the lower score average and percentage
of correct results in IgM detection by IIF compared with
ELISA assays.
The high rate of IgG false positives reported by the
participants for the sample containing anti-WNV anti-
bodies is striking. This false reactivity has been recog-
nized by the manufacturers of commercial assays, but
the question remains on how to address it in countries
with WNV circulation. Higher specificity was attained by
some laboratories using assays aimed at detecting se-
condary infections, namely the Standard Diagnostics or
the Panbio Dengue IgG capture assay, though at the cost
of lower sensitivity. As these laboratories experienced
also less cross-reactivity with tick-borne encephalitis,
yellow fever, or Japanese encephalitis, this alternative
approach deserves consideration.
Lastly, a small number of laboratories made false-
positive calls on the negative control samples (Additional
file 2 and Additional file 3), which is suggestive of deficien-
cies in their operating procedures or poor standardization
of in-house protocols.
A critical point in the design of an international EQA
exercise is the shipment of samples. ENIVD freeze-dried
sample panels are always sent by regular mail at room
temperature. Sample quality may arguably be affected by
both the preparation process and by delivery time to the
laboratory: in some instances, up to several weeks under
tropical conditions. However, experience from this and
previous EQAs shows that the impact of temperature
and delivery time on sample quality is very limited or
non-existent. Only in a few cases have changes in the
physical characteristics of the material been reported
(one laboratory [#33] in this EQA reported difficulties in
reconstituting the samples but its results were not
affected). Similarly, the results obtained by the laborator-
ies show that the quality of samples was not a limitation
in the EQA. Nevertheless, we are interested in improv-
ing the quality of the ENIVD EQA panels and different
sample stabilizers are being tested for that purpose.
Here, a reference sample was prepared by freeze-drying,
and two additional aliquots of the same sample were re-
spectively prepared using two commercial stabilizers.
Assay performance was consistent across the three re-
lated samples. A serum with a high antibody titre was
selected for this stability test; in future EQAs, samples
with a titre closer to the limit of detection may be
Domingo et al. BMC Infectious Diseases  (2015) 15:167 Page 8 of 8included for a more stringent assessment of the effect of
stabilizing reagents on assay sensitivity.
A previous EQA on dengue serology was performed by
ENIVD in 2002, and eleven laboratories participated in
both this and the present EQA [17]. Direct performance
comparisons between the two EQAs are not possible, be-
cause the 2002 panel included no sera from non-dengue
flaviviral infections, nor was quantitative titration used in
the initial characterization of the samples.
Conclusions
From the results of this EQA, we conclude that the qual-
ity of dengue IgM-based serological diagnosis depends
on the type of protocol used by the laboratories, with
those using commercial antibody capture ELISA formats
significantly outperforming the others. We hope that the
results we describe will help improve the sensitivity stan-
dards for IgM detection among the dengue community.
The performance of IgG detection seemed to be linked
mostly to particulars of a technique as practiced by indi-
vidual laboratories, and cross-reactivity remains a
serious issue. IgG capture ELISA formats seem to pro-
vide better specificity, but the trade-off observed be-
tween specificity and sensitivity has to be considered.
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